This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS
by Zacks Equity Research
Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS with statistical significance.
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
by Zacks Equity Research
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai's Leqembi in the EU for early AD.
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
by Zacks Equity Research
CMPX stock more than doubles following updates regarding the pipeline development programs and current cash position by the company.
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
by Zacks Equity Research
The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
CMRX Stock Skyrockets in 3 Months: Here's What You Should Know
by Zacks Equity Research
Chimerix stock surges 324% in three months following NDA submission for high-grade glioma drug, dordaviprone, for accelerated approval in the United States.
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases
by Zacks Equity Research
The FDA clears ALLO's investigational new drug application to start clinical studies on its investigational CAR T product, ALLO-329, for autoimmune diseases.
Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Castle Biosciences (CSTL) points to a 51.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma. A decision is due on May 26, 2025.
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
by Zacks Equity Research
Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.
FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication
by Zacks Equity Research
The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United States.
PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor
by Zacks Equity Research
A Bloomberg article suggests activist investor Starboard cut Pfizer some slack by not nominating any director on the company's board this year.
MRK Reports Mixed Keytruda Combo Study Data in Gastroesophageal Cancer
by Zacks Equity Research
The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal adenocarcinoma.
NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss
by Zacks Equity Research
Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to placebo in an obesity study.
Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why
by Zacks Equity Research
AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.
Is it a Good Idea to Invest in Beam Therapeutics Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in BEAM stock now may turn out to be a prudent move.
Axsome Shares Rise 19% in a Month: What's Driving the Rally?
by Zacks Equity Research
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while Sunosi diversifies its business.
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study
by Zacks Equity Research
Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why
by Zacks Equity Research
KROS stock crashes 81% in three months after dosing with cibotercept was halted in a phase II lung disease study due to adverse pericardial effusion events.
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
by Zacks Equity Research
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
by Zacks Equity Research
The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on July 22, 2025.
J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use
by Zacks Equity Research
The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.
4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now
by Anirudha Bhagat
Buy these four top-ranked stocks, CSTL, OPFI, GCT and QIFU, with solid net profit margins to enhance your portfolio returns.
Nanobiotix Stock Gains as Dosing Begins in Mid-Stage NSCLC Study
by Zacks Equity Research
NBTX stock rises following initiation of dosing in a mid-stage NSCLC study evaluating a potential first-in-class radioenhancer, JNJ-1900.
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
by Zacks Equity Research
The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
by Zacks Equity Research
The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.